20030645 65

31 10CT 2003

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 November 2002 (14.11.2002)

PCT

(10) International Publication Number
WO 02/089787 A1

(51) International Patent Classification[7]: A61K 31/20, A61P 19/02, 25/24, 25/28, 35/00 // A61K 31/415, 31/19, 31/405

(21) International Application Number: PCT/GB02/02145

(22) International Filing Date: 9 May 2002 (09.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
011282.0 9 May 2001 (09.05.2001) GB

(71) Applicant *(for all designated States except US)*: **LAXDALE LIMITED** [GB/GB]; Kings Park House, Laurelhill Business Park, Polmaise Road, Stirling FK7 9JQ (GB).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **HORROBIN, David, Frederick** [GB/GB]; Kings Park House, Laurelhill Business Park, Polmaise Road, Stirling FK7 9JQ (GB).

(74) Agent: **WAKERLEY, Helen, Rachael**; Reddie & Grose, 16 Theobalds Road, London WC1X 8 PL (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: POTENTIATION OF THERAPEUTIC EFFECTS OF FATTY ACIDS

ESSENTIAL FATTY ACID (EFA) METABOLISM

	n-6 series		n-3 series	
18:2n-6	LINOLEIC		ALPHA LINOLENIC	18:3n-3
	↓	Delta-6-desaturation	↓	
18:3n-6	GAMMA-LINOLENIC		STEARIDONIC	18:4n-3
	↓	Elongation	↓	
20:3n-61	DIHOMOGAMMALINOLENIC		EICOSA TETRAENOIC (n-3)	20:4n-3
	↓	Delta-5-desaturation	↓	
20:4n-6	ARACHIDONIC		EICOSAPENTAENOIC	20:5n-3
	↓	Elongation	↓	
22:4n-6	ADRENIC		DOCOSAPENT AENOIC (n-3)	22:5n-3
	↓	Delta-4-desaturation	↓	
22:5n-6	DOCOSAPENTAENOIC (n-6)		DOCOSAHEXAENOIC	22:6n-3

(57) Abstract: The oral administration of an essential fatty acid, preferably eicosapentaenoic acid, at a defined purity together with an inhibitor of COX-1 or COX-2 or LOX or one or more of the FACL enzymes gives improved therapeutic results over administrationof the fatty acid alone.

WO 02/089787 A1

162162

ACTION